CA-ATTACKIQ
20.4.2022 15:02:05 CEST | Business Wire | Press release
AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced a new integration with Vectra®, an AI-driven threat detection and response platform that enables joint customers to detect attacks that have bypassed existing security controls and ensure rapid response to the latest threats.
"In today's hyper-complex threat environment, organizations must think proactively and adopt advanced security capabilities to prevent successful attacks," said Carl Wright, Chief Commercial Officer at AttackIQ. "This integration will allow our customers to validate the efficacy of the Vectra AI platform by utilizing AttackIQ's PCAP replay and related network scenarios to find and fix coverage gaps throughout their security infrastructure before adversaries exploit them."
AttackIQ operates under the "assume breach" mindset, recognizing that it is not a question of if but when an intruder will break past an organization's perimeter defense. Leveraging automated breach and attack simulation technology and the MITRE ATT&CK framework, the AttackIQ Security Optimization Platform enables organizations to measure their security controls performance, identify misconfigurations or gaps in coverage, and focus resources on areas with the highest probability of risk exposure.
"It is exciting to see AttackIQ and Vectra joining forces to help customers enable a proactive, threat-informed defense," said Geert Busse, Head of Next-Gen Solutions Pre Sales EMEA, Westcon. "As key vendors in our Westcon Next Generation Solutions go-to-market strategy, these two organizations are the backbone of our technology pillar, focusing on defense against emerging threats by delivering automation, integration and efficiency that our industry needs to detect and stop the latest generation of Threat Actors."
The Vectra Platform uses security-led artificial intelligence (AI) to power threat detection and response to ensure speed, precision, and efficiency in surfacing and stopping attacks before devastating impact. The platform captures data from network packets and logs that give insight into companies' public cloud and SaaS environment, federated identity, and data center networks. Vectra's patented approach to applying AI to detection analyzes all detection to prioritize threats and map events to MITRE ATT&CK framework without noise and hunting. It further drives appropriate remediation and rapid response through other tools already implemented in your security stack.
The AttackIQ Security Optimization Platform integration with the Vectra Threat Detection and Response Platform is available today.
To learn more about this integration and see it in action register for the May 5th demo here: https://attackiq.com/get-a-demo/weekly-demo/ .
About AttackIQ
AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry's first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free award-winning AttackIQ Academy , open Preactive Security Exchange, and partnership with MITRE Engenuity's Center for Threat-Informed Defense . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .
About Vectra AI
Vectra® is a leader in threat detection and response for hybrid and multi-cloud enterprises. The Vectra platform uses AI to detect threats at speed across public cloud, identity, SaaS applications, and data centers. Only Vectra optimizes AI to detect attacker methods—the TTPs at the heart of all attacks—rather than simplistically alerting on "different". The resulting high-fidelity threat signal and clear context enables security teams to respond to threats sooner and to stop attacks in progress faster. Organizations worldwide rely on Vectra for cybersecurity resilience in the face of dangerous cyber threats and to prevent ransomware, supply chain compromise, identity takeovers, and other cyberattacks from impacting their businesses. For more information, visit vectra.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005006/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
